NAV

ST-101

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
ST-101
DrugBank Accession Number
DB12621
Background

ST-101 is a small peptide antagonist of C/EBPβ and T-type calcium channel activator. ST101 has been used in trials studying the treatment of Essential Tremor and Alzheimer's Disease.1

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 236.274
Monoisotopic: 236.094963014
Chemical Formula
C15H12N2O
Synonyms
  • C/EBP Beta Antagonist ST101
  • D-Arginine, D-valyl-D-alanyl-D-α-glutamyl-D-alanyl-D-arginyl-D-α-glutamyl-D-α-glutamyl-D-leucyl-D-α-glutamyl-D-arginyl-D-leucyl-D-α-glutamyl-D-alanyl-D-arginyl-D-leucylglycyl-D-glutaminyl-D-alanyl-D-arginylglycyl-D-α-glutamyl-D-leucyl-D-lysyl-D-lys
  • H-D-valyl1-D-alanyl-D-glutamyl-D-alanyl-D-arginyl5-D-glutamyl-D-glutamyl-D-leucyl-D-glutamyl-D-arginyl10-D-leucyl-D-glutamyl-D-alanyl-D-arginyl-D-leucyl15-glycyl-D-glutaminyl-D-alanyl-D-arginyl-glycyl20-D-glutamyl-D-leucyl-D-lysyl-D-lysyl-D-tryptophyl25-D-lysyl-D-methionyl-D-arginyl-D-arginyl-D-asparaginyl30-D-glutaminyl-D-phenylalanyl-D-tryptophyl-D-leucyl-D-lysyl35-D-leucyl-D-glutaminyl-D-arginine
  • ST-101 (D-AMINO ACID PEPTIDE)
  • ST101 (peptide)
External IDs
  • ST 101
  • ST101
  • ZSET-1446

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as imidazopyridinones. These are compounds containing an imidazopyridine moiety where the pyridine ring bears a ketone group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Imidazopyridines
Sub Class
Imidazopyridinones
Direct Parent
Imidazopyridinones
Alternative Parents
Alpha amino acids and derivatives / Indanes / Pyridinones / Dihydropyridines / Imidazolinones / N-acylimines / Propargyl-type 1,3-dipolar organic compounds / Enamines / Carboximidamides / Carboxamidines
show 4 more
Substituents
2-imidazoline / Alpha-amino acid or derivatives / Amidine / Amine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboximidamide / Carboxylic acid amidine
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
7TTT61784C
CAS number
887603-94-3
InChI Key
QZWYXEBIQWJXAR-UHFFFAOYSA-N
InChI
InChI=1S/C15H12N2O/c18-14-15(17-8-4-3-7-13(17)16-14)9-11-5-1-2-6-12(11)10-15/h1-8H,9-10H2
IUPAC Name
1',3'-dihydro-2H-spiro[imidazo[1,2-a]pyridine-3,2'-indene]-2-one
SMILES
O=C1N=C2C=CC=CN2C11CC2=CC=CC=C2C1

References

General References
  1. Papazoglou A, Arshaad MI, Henseler C, Daubner J, Broich K, Hescheler J, Ehninger D, Haenisch B, Weiergraber M: Ca(v)3 T-Type Voltage-Gated Ca(2+) Channels and the Amyloidogenic Environment: Pathophysiology and Implications on Pharmacotherapy and Pharmacovigilance. Int J Mol Sci. 2022 Mar 22;23(7):3457. doi: 10.3390/ijms23073457. [Article]
PubChem Compound
10220323
PubChem Substance
347828833
ChemSpider
8395815
ChEMBL
CHEMBL4297437
ZINC
ZINC000001491487

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAlzheimer's Disease (AD)2
2CompletedTreatmentEssential Tremor1
1, 2RecruitingTreatmentBrain Cancer / Breast Cancer / Glioblastoma Multiforme (GBM) / High Grade Glioma: Glioblastoma (GBM) / Metastatic Breast Cancer / Metastatic Melanoma / Metastatic Prostate Cancer / Newly diagnosed Glioblastoma Multiforme (GBM) / Prostate Cancer / Recurrent Glioblastoma / Recurrent Melanoma / Stage IV Melanoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.171 mg/mLALOGPS
logP2.04ALOGPS
logP1.84Chemaxon
logS-3.1ALOGPS
pKa (Strongest Basic)0.23Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area32.67 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity70.59 m3·mol-1Chemaxon
Polarizability25.05 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 20, 2016 23:15 / Updated at September 15, 2023 10:37